glp 1/gip agonist The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review GLP1-GIP receptor co-agonists: a promising

W., Thielke, D., Viljoen, A., & McCrimmon, R

Two interventions have a strong evidence base and should, in my view, be part of every GLP-1 treatment discussion

Studies have shown that semaglutide upregulates the expression of ITPR1 and ADCY5 in CRC by activating the GLP-1 receptor, which, in turn, inhibits the motility of CRC cells [88]

The semaglutide and tirzepatide trials changed that expectation: Semaglutide 2.4 mg once weekly produced average weight loss around 15% at ~68 weeks in adults without diabetes, with a substantial fraction of participants losing 1520% of baseline weight

Treatments for CKD in People Living with T2DM Findings from systematic reviews and meta-analyses indicate that improved renal outcomes can be achieved through obesity management [8], intensive glycemic control using glucose-lowering medications [9], and anti-hypertension drugs [10]